Yoonjin Kwak

Yoonjin Kwak

Auto-generated profile, based on publicly available information

Yoonjin Kwak

Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
TKTae Han Kim
Tae Han Kim
IKIn-Ho Kim
In-Ho Kim
SKSeung Joo Kang
Seung Joo Kang
MCMiyoung Choi
Miyoung Choi
BKBaek-Hui Kim
Baek-Hui Kim
OTon behalf of The Development Working Groups for the Korean Practice Guidelines for Gastric Cancer 2022 Task Force Team
on behalf of The Development Working Groups for the Korean Practice Guidelines for Gastric Cancer 2022 Task Force Team
Kim TH, et al. J Gastric Cancer. 2023 Jan;23:e11. https://doi.org/10.5230/jgc.2023.23.e11

15 September 2020 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
HHHye Jung Hwang
Hye Jung Hwang
SNSoo Kyung Nam
Soo Kyung Nam
HPHyunjin Park
Hyunjin Park
YPYujun Park
Yujun Park
JKJiwon Koh
Jiwon Koh
HLHye Seung Lee
Hye Seung Lee
Recently, molecular classifications of gastric cancer (GC) have been proposed that include TP53 mutations and their functional activity. We aimed to demonstrate the correlation between p53 immunohistochemistry (IHC) and TP53 mutations as well as their clinicopathological significance in GC. Deep targeted sequencing was performed using surgical or biopsy specimens from 120 patients with GC. IHC for p53 was performed and interpreted as strong, weak, or negative expression. In 18 cases (15.0%) with discrepant TP53 mutation and p53 IHC results, p53 IHC was repeated. Strong expression of p53 was associated with TP53 missense mutations, negative expression with other types of mutations, and weak expression with wild-type TP53 (p<.001). The sensitivity for each category was 90.9%, 79.0%, and 80.9%, and the specificity was 95.4%, 88.1%, and 92.3%, respectively. The TNM stage at initial diagnosis exhibited a significant correlation with both TP53 mutation type (p=.004) and p53 expression status (p=.029). The Kaplan-Meier survival analysis for 109 stage II and III GC cases showed that patients with TP53 missense mutations had worse overall survival than those in the wild-type and other mutation groups (p=.028). Strong expression of p53 was also associated with worse overall survival in comparison to negative and weak expression (p=.035). Results of IHC of the p53 protein may be used as a simple surrogate marker of TP53 mutations. However, negative expression of p53 and other types of mutations of TP53 should be carefully interpreted because of its lower sensitivity and different prognostic implications.

15 January 2023 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
YPYoung Soo Park
Young Soo Park
MKMyeong-Cherl Kook
Myeong-Cherl Kook
BKBaek-Hui Kim
Baek-Hui Kim
HLHye Seung Lee
Hye Seung Lee
DKDong Wook Kang
Dong Wook Kang
TPThe Gastrointestinal Pathology Study Group of the Korean Society of Pathologists
The Gastrointestinal Pathology Study Group of the Korean Society of Pathologists
The first edition of ‘A Standardized Pathology Report for Gastric Cancer’ was initiated by the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists and published 17 years ago. Since then, significant advances have been made in the pathologic diagnosis, molecular genetics, and management of gastric cancer (GC). To reflect those changes, a committee for publishing a second edition of the report was formed within the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. This second edition consists of two parts: standard data elements and conditional data elements. The standard data elements contain the basic pathologic findings and items necessary to predict the prognosis of GC patients, and they are adequate for routine surgical pathology service. Other diagnostic and prognostic factors relevant to adjuvant therapy, including molecular biomarkers, are classified as conditional data elements to allow each pathologist to selectively choose items appropriate to the environment in their institution. We trust that the standardized pathology report will be helpful for GC diagnosis and facilitate large-scale multidisciplinary collaborative studies.

1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
Dong Jin KimDong Jin Kim
Dong Jin Kim
JSJeong Ho Song
Jeong Ho Song
JPJi-Hyeon Park
Ji-Hyeon Park
SKSojung Kim
Sojung Kim
SPSin Hye Park
Sin Hye Park
TAThe Information Committee of the Korean Gastric Cancer Association
The Information Committee of the Korean Gastric Cancer Association
Kim DJ, et al. J Gastric Cancer. 2024 Dec;25:e8. https://doi.org/10.5230/jgc.2025.25.e8

15 May 2024 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
SASoomin Ahn
Soomin Ahn
YKYoonjin Kwak
Yoonjin Kwak
GKGui Young Kwon
Gui Young Kwon
KKKyoung-Mee Kim
Kyoung-Mee Kim
MKMoonsik Kim
Moonsik Kim
HLHye Seung Lee
Hye Seung Lee
Nivolumab plus chemotherapy in the first-line setting has demonstrated clinical efficacy in patients with human epidermal growth factor receptor 2–negative advanced or metastatic gastric cancer, and is currently indicated as a standard treatment. Programmed death-ligand 1 (PD-L1) expression is an important biomarker for predicting response to anti–programmed death 1/PD-L1 agents in several solid tumors, including gastric cancer. In the CheckMate-649 trial, significant clinical improvements were observed in patients with PD-L1 combined positive score (CPS) ≥ 5, determined using the 28-8 pharmDx assay. Accordingly, an accurate interpretation of PD-L1 CPS, especially at a cutoff of 5, is important. The CPS method evaluates both immune and tumor cells and provides a comprehensive assessment of PD-L1 expression in the tumor microenvironment of gastric cancer. However, CPS evaluation has several limitations, one of which is poor interobserver concordance among pathologists. Despite these limitations, clinical indications relying on PD-L1 CPS are increasing. In response, Korean gastrointestinal pathologists held a consensus meeting for the interpretation of PD-L1 CPS in gastric cancer. Eleven pathologists reviewed 20 PD-L1 slides with a CPS cutoff close to 5, stained with the 28-8 pharmDx assay, and determined the consensus scores. The issues observed in discrepant cases were discussed. In this review, we present cases of gastric cancer with consensus PD-L1 CPS. In addition, we briefly touch upon current practices and clinical issues associated with assays used for the assessment of PD-L1 expression in gastric cancer.

15 October 2024 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
DHDong-Seok Han
Dong-Seok Han
YKYoonjin Kwak
Yoonjin Kwak
SLSeungho Lee
Seungho Lee
SNSoo Kyung Nam
Soo Kyung Nam
SKSeong-Ho Kong
Seong-Ho Kong
HYHan-Kwang Yang
Han-Kwang Yang
Purpose Gastric cancer exhibits molecular heterogeneity, with the microsatellite instability–high (MSI-H) subtype drawing attention for its distinct features. Despite a higher survival rate, MSI-H gastric cancer lack significant benefits from conventional chemotherapy. The immune checkpoint inhibitors, presents a potential avenue, but a deeper understanding of the tumor immune microenvironment of MSI-H gastric cancer is essential.Materials and Methods We explored the molecular characteristics of CD8+ T-cell subtypes in three MSI-H and three microsatellite stable (MSS) gastric cancer samples using single-cell RNA sequencing and spatial transcriptome analysis.Results In MSI-H gastric cancer, significantly higher proportions of effector memory T cell (Tem), exhausted T cell (Tex), proliferative exhausted T cell (pTex), and proliferative T cell were observed, while MSS gastric cancer exhibited significantly higher proportions of mucosal-associated invariant T cell and natural killer T cell. In MSI-H gastric cancer, Tex and pTex exhibited a significant upregulation of the exhaustion marker LAG3, as well as elevated expression of effector function markers such as IFNG, GZMB, GZMH, and GZMK, compared to those in MSS gastric cancer. The interferon γ (IFN-γ) signaling pathway of Tex and pTex was retained compared to those of MSS gastric cancer. The spatial transcriptome analysis demonstrates the IFN-γ signaling pathway between neighboring Tex and malignant cell, showcasing a significantly elevated interaction in MSI-H gastric cancer.Conclusion Our study reveals novel finding indicating that IFN-γ signaling pathway is retained in Tex and pTex of MSI-H gastric cancer, offering a comprehensive perspective for future investigations into immunotherapy for gastric cancer.